Alan Melcher Selected Research

Oncolytic Virotherapy

1/2022	CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma.
3/2021	Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate Tumors.
1/2021	APOBEC and Cancer Viroimmunotherapy: Thinking the Unthinkable.
1/2019	Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment.
12/2018	APOBEC3 Mediates Resistance to Oncolytic Viral Therapy.
6/2018	Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus.
1/2016	Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances.
1/2014	Applications of coxsackievirus A21 in oncology.
7/2013	Future clinical potential of oncolytic virotherapy for pediatric CNS tumors.
11/2011	Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alan Melcher Research Topics

Disease

78	Neoplasms (Cancer) 01/2022 - 06/2002
23	Melanoma (Melanoma, Malignant) 01/2022 - 10/2002
14	Vesicular Stomatitis 01/2021 - 10/2002
6	Infections 01/2021 - 10/2012
6	Experimental Melanoma 04/2016 - 03/2005
5	Brain Neoplasms (Brain Tumor) 01/2022 - 04/2016
4	Glioma (Gliomas) 01/2022 - 02/2015
4	Prostatic Neoplasms (Prostate Cancer) 03/2021 - 12/2007
4	Virus Diseases (Viral Diseases) 01/2021 - 10/2012
3	Carcinoma (Carcinomatosis) 07/2021 - 03/2007
3	Colorectal Neoplasms (Colorectal Cancer) 01/2019 - 08/2007
2	Rectal Neoplasms (Rectal Cancer) 01/2021 - 08/2009
2	Bites and Stings (Sting) 07/2020 - 01/2020
2	Head and Neck Neoplasms (Head and Neck Cancer) 01/2020 - 08/2013
2	Liver Neoplasms (Liver Cancer) 01/2018 - 08/2013
2	Neoplasm Metastasis (Metastasis) 01/2018 - 01/2008
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2016 - 02/2015
1	Ovarian Epithelial Carcinoma 07/2021
1	Glioblastoma (Glioblastoma Multiforme) 01/2021
1	Squamous Cell Carcinoma of Head and Neck 01/2021
1	Cytokine Release Syndrome 12/2020
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2019
1	Lung Neoplasms (Lung Cancer) 01/2019
1	Sarcoma (Soft Tissue Sarcoma) 01/2019
1	Urinary Bladder Neoplasms (Bladder Cancer) 06/2018
1	Non-Muscle Invasive Bladder Neoplasms 06/2018
1	Wounds and Injuries (Trauma) 11/2017
1	Diffuse Intrinsic Pontine Glioma 06/2017

Drug/Important Bio-Agent (IBA)

24	AntigensIBA 01/2022 - 10/2002
9	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2018
9	Neoplasm Antigens (Tumor Antigens)IBA 01/2019 - 10/2002
8	Proteins (Proteins, Gene)FDA Link 01/2021 - 03/2007
8	CytokinesIBA 01/2020 - 09/2007
6	VaccinesIBA 01/2020 - 10/2002
5	Antiviral Agents (Antivirals)IBA 01/2021 - 11/2008
4	Complementary DNA (cDNA)IBA 01/2016 - 11/2011
3	Neutralizing AntibodiesIBA 01/2021 - 01/2008
3	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 09/2004
3	EpitopesIBA 01/2020 - 02/2006
3	talimogene laherparepvecIBA 01/2018 - 08/2013
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2017 - 05/2010
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2011 - 01/2008
3	CD40 Ligand (CD40L)IBA 04/2010 - 09/2006
3	Interleukin-2 (IL2)IBA 01/2009 - 07/2008
3	Membrane Glycoproteins (Membrane Glycoprotein)IBA 02/2006 - 10/2002
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2022 - 10/2014
2	Interferon Type IIBA 03/2021 - 04/2010
2	Interleukin-6 (Interleukin 6)IBA 12/2020 - 11/2017
2	InterferonsIBA 01/2020 - 02/2011
2	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 06/2018 - 01/2018
2	PLX 4720IBA 05/2015 - 05/2015
2	Ganciclovir (Cytovene)FDA LinkGeneric 02/2015 - 09/2006
2	Conditioned Culture MediaIBA 02/2015 - 02/2011
2	Interferon LambdaIBA 01/2013 - 06/2010
2	Therapeutic UsesIBA 10/2011 - 01/2011
2	Docetaxel (Taxotere)FDA Link 06/2011 - 11/2010
2	Biological ProductsIBA 06/2011 - 10/2009
2	Cancer VaccinesIBA 03/2010 - 09/2003
2	AutoantigensIBA 12/2007 - 03/2005
2	Glycoproteins (Glycoprotein)IBA 02/2006 - 10/2002
1	sargramostim (Leukine)FDA Link 01/2022
1	Programmed Cell Death 1 ReceptorIBA 03/2021
1	LigandsIBA 03/2021
1	Member 14 Tumor Necrosis Factor ReceptorsIBA 03/2021
1	Adenosine (Adenocard)FDA LinkGeneric 03/2021
1	Peptides (Polypeptides)IBA 01/2021
1	Transforming Growth Factor beta (TGF-beta)IBA 01/2021
1	Interferon-betaIBA 01/2021
1	Fibrinogen (Factor I)FDA Link 01/2021
1	CytosineIBA 01/2021
1	Biomarkers (Surrogate Marker)IBA 01/2021
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	Viral RNAIBA 01/2021
1	Pharmaceutical PreparationsIBA 01/2021
1	APOBEC-1 DeaminaseIBA 01/2021
1	MutagensIBA 01/2021
1	Matrix Metalloproteinase 14 (MT1-MMP)IBA 01/2021
1	Cytidine DeaminaseIBA 01/2020
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2020
1	ceralasertibIBA 01/2019
1	cibisatamabIBA 01/2019
1	IpilimumabIBA 01/2019
1	Melphalan (Alkeran)FDA LinkGeneric 01/2019
1	CalreticulinIBA 06/2018
1	Mitomycin (Mitomycin-C)FDA LinkGeneric 06/2018
1	MTOR InhibitorsIBA 01/2018
1	Sirolimus (Rapamycin)FDA Link 01/2018
1	dipinacoline glutamateIBA 06/2017
1	Glycogen Synthase (Synthase I)IBA 06/2017

Therapy/Procedure

47	Therapeutics 01/2022 - 10/2002
28	Immunotherapy 03/2021 - 06/2002
17	Oncolytic Virotherapy 01/2022 - 01/2008
14	Drug Therapy (Chemotherapy) 07/2021 - 08/2007
7	Radiotherapy 01/2021 - 08/2009
4	Biological Therapy 06/2018 - 07/2008
2	Neoadjuvant Therapy 01/2021 - 01/2016
2	Injections 01/2009 - 09/2006
2	Intradermal Injections 09/2006 - 09/2004
1	Transplantation 01/2018